Reports
Sale
Urinary Incontinence Drugs Market Size, Share, Forecast: By Incontinence Type: Urge Incontinence, Overflow Incontinence, Stress Incontinence, Mixed Incontinence, Other Type; By Drug Type: Anticholinergic, Skeletal Muscle Relaxants, Antidepressants, Others; By Distribution Channel; Regional Analysis; Supplier Landscape; 2024-2032
Urinary Incontinence Drugs Market Outlook
The urinary incontinence drugs market size was valued at USD 12028.45 million in 2023, driven by the increasing geriatric population across the 7 major markets. The market size is anticipated to grow at a CAGR of 7% during the forecast period of 2024-2032 to achieve a value of USD 22199 million by 2032.
Urinary Incontinence Drugs: Introduction
Urinary incontinence is a medical condition in which the patient suffers from unintentional passing of urine. It is a common problem affecting millions of people around the world. There are several types of urinary incontinence, including stress incontinence – when urine leaks out at times when the patient’s bladder is under pressure; for example, when they cough or laugh.
Urinary Incontinence Drugs Market Analysis
The urinary incontinence drugs market is witnessing significant developments that are expected to influence market growth positively. For example, Versameb's VMB-100, an investigational drug encoding human insulin-like growth factor-1 (IGF-1), has received FDA acceptance for an investigational new drug (IND) application. This marks a significant step toward addressing stress urinary incontinence (SUI) exclusively in female patients. The initiation of a phase 2A open-label dose ascending study in the first half of 2024 aims to evaluate VMB-100's safety, tolerability, and efficacy in treating moderate SUI.
Additionally, a potential breakthrough in the treatment of overactive bladder (OAB) and urge urinary incontinence (UUI) has emerged with the investigational gene therapy URO-902. Results from a phase 2A trial indicate that single-dose URO-902, administered at 24 mg and 48 mg, exhibited clinically relevant reductions in daily micturitions, urgency episodes, and UUI episodes compared to a placebo. This promising data suggests a novel and effective treatment strategy for women facing these conditions, further expected to support the urinary incontinence drugs market growth.
Furthermore, Alembic Pharmaceuticals has received final approval from the FDA for Fesoterodine Fumarate Extended-Release tablets, designed to treat overactive bladder in adults. The approval positions this medication as therapeutically equivalent to the reference listed drug product Toviaz Extended-Release Tablets by Pfizer Inc. This milestone enhances the available options for managing overactive bladder and contributes to the overall growth of the urinary incontinence drugs market. The collective impact of these developments, encompassing innovative therapies and expanded treatment options, is expected to drive market growth by meeting the evolving needs of patients and offering more effective solutions for urinary incontinence.
Urinary Incontinence Drugs Market Segmentations
Market Breakup by Incontinence Type
- Urge Incontinence
- Overflow Incontinence
- Stress Incontinence
- Mixed Incontinence
- Other Type
Market Breakup by Drug Type
- Anticholinergic
- Skeletal Muscle Relaxants
- Antidepressants
- Alpha Blockers
- Topical Estrogens
- Others
Market Breakup by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online pharmacies
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
Urinary Incontinence Drugs Market Overview
The market for urinary incontinence treatment drugs is poised for substantial growth, primarily driven by the rising prevalence of urinary incontinence, a condition that is expected to escalate the demand for effective treatment drugs. The increasing geriatric population worldwide is a contributing factor to the growth of the market.
As regulatory bodies continue to grant approvals for new drugs in this category, it is further expected to propel the urinary incontinence drugs market growth. This positive trend can be significantly exhibited by the situation in North America, where the urinary incontinence treatment drugs market is anticipated to witness significant expansion in the near future. Factors contributing to this growth include the high prevalence of orthopedic disorders and dysfunctions, favorable health reimbursement policies, and an increased level of awareness.
Moreover, the increasing incidence of neurological disorders in the region adds another dimension to the market's expansion, boosting the demand for urinary incontinence treatment drugs. With these drivers contributing to the market, the urinary incontinence drugs market is expected to experience sustained growth, meeting the healthcare needs of an expanding patient population and driving innovation in the field.
Urinary Incontinence Drugs Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Johnson & Johnson
- Pfizer
- Astellas Pharma
- Allergan
- Takeda Pharmaceuticals Company
- Merck KGaA.
- Sanofi S.A.
- Kissei Pharmaceutical
- Kyorin Holding
- Urovant Sciences
- Cook MyoSite
- elicept Therapeutics
- Astellas Pharma
Please note that this list only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Incontinence Type |
|
| Breakup by Drug Type |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Urinary Incontinence Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Urinary Incontinence Drugs Overview
5.1 Guidelines and Stages
5.2 Pathophysiology
5.3 Screening and Diagnosis
5.4 Treatment Pathway
6 Patient Profile
6.1 Patient Profile Overview
6.2 Patient Psychology and Emotional Impact Factors
6.3 Risk Assessment and Treatment Success Rate
7 Urinary Incontinence Drugs Epidemiology Analysis – 7MM
7.1 7MM Epidemiology Scenario Overview (2017-2032)
7.2 United States Urinary Incontinence Drugs Epidemiology Forecast (2017-2032)
7.3 EU-4 and United Kingdom Urinary Incontinence Drugs Epidemiology Forecast (2017-2032)
7.3.1 Germany Urinary Incontinence Drugs Epidemiology Forecast (2017-2032)
7.3.2 France Urinary Incontinence Drugs Epidemiology Forecast (2017-2032)
7.3.3 Italy Urinary Incontinence Drugs Epidemiology Forecast (2017-2032)
7.3.4 Spain Urinary Incontinence Drugs Epidemiology Forecast (2017-2032)
7.3.5 United Kingdom Urinary Incontinence Drugs Epidemiology Forecast (2017-2032)
7.4 Japan Urinary Incontinence Drugs Epidemiology Forecast (2017-2032)
8 Urinary Incontinence Drugs Market Overview – 7MM
8.1 Urinary Incontinence Drugs Market Historical Value (2017-2023)
8.2 Urinary Incontinence Drugs Market Forecast Value (2024-2032)
9 Urinary Incontinence Drugs Market Landscape – 7MM
9.1 Urinary Incontinence Drugs Developers Landscape
9.1.1 Analysis by Year of Establishment
9.1.2 Analysis by Company Size
9.1.3 Analysis by Region
9.2 Urinary Incontinence Drugs Product Landscape
9.2.1 Analysis by Products
9.2.2 Analysis by Indications
9.2.3 Analysis by Route of Administration
10 Urinary Incontinence Drugs Challenges and Unmet Needs
10.1 Treatment Pathway Challenges
10.2 Compliance and Drop-Out Analysis
10.3 Awareness and Prevention Gaps
11 Cost of Treatment
12 Urinary Incontinence Drugs Market Dynamics
12.1 Market Drivers and Constraints
12.2 SWOT Analysis
12.3 Porter’s Five Forces Model
12.4 Key Demand Indicators
12.5 Key Price Indicators
12.6 Industry Events, Initiatives, and Trends
12.7 Value Chain Analysis
13 Urinary Incontinence Drugs Market Segmentation – 7MM
13.1 Urinary Incontinence Drugs Market by Incontinence Type
13.1.1 Market Overview
13.1.2 Urge Incontinence
13.1.3 Overflow Incontinence
13.1.4 Stress Incontinence
13.1.5 Mixed Incontinence
13.1.6 Other Type
13.2 Urinary Incontinence Drugs Market by Drug Type
13.2.1 Market Overview
13.2.2 Anticholinergic
13.2.3 Skeletal Muscle Relaxants
13.2.4 Antidepressants
13.2.5 Alpha Blockers
13.2.6 Topical Estrogens
13.2.7 Others
13.3 Urinary Incontinence Drugs Market by Distribution Channel
13.3.1 Market Overview
13.3.2 Hospital Pharmacies
13.3.3 Retail Pharmacies
13.3.4 Online pharmacies
13.4 Urinary Incontinence Drugs Market by Region
13.4.1 Market Overview
13.4.2 United States
13.4.3 EU-4 and the United Kingdom
13.4.3.1 Germany
13.4.3.2 France
13.4.3.3 Italy
13.4.3.4 Spain
13.4.3.5 United Kingdom
13.4.4 Japan
14 United States Urinary Incontinence Drugs Market
14.1 Urinary Incontinence Drugs Market Historical Value (2017-2023)
14.2 Urinary Incontinence Drugs Market Forecast Value (2024-2032)
14.3 Urinary Incontinence Drugs Market by Disease Type
14.4 Urinary Incontinence Drugs Market by Treatment Type
15 EU-4 and United Kingdom Urinary Incontinence Drugs Market
15.1 Urinary Incontinence Drugs Market Historical Value (2017-2023)
15.2 Urinary Incontinence Drugs Market Forecast Value (2024-2032)
15.3 Germany Urinary Incontinence Drugs Market Overview
15.3.1 Urinary Incontinence Drugs Market by Disease Type
15.3.2 Urinary Incontinence Drugs Market by Treatment Type
15.4 France Urinary Incontinence Drugs Market Overview
15.4.1 Urinary Incontinence Drugs Market by Disease Type
15.4.2 Urinary Incontinence Drugs Market by Treatment Type
15.5 Italy Urinary Incontinence Drugs Market Overview
15.5.1 Urinary Incontinence Drugs Market by Disease Type
15.5.2 Urinary Incontinence Drugs Market by Treatment Type
15.6 Spain Urinary Incontinence Drugs Market Overview
15.6.1 Urinary Incontinence Drugs Market by Disease Type
15.6.2 Urinary Incontinence Drugs Market by Treatment Type
15.7 United Kingdom Urinary Incontinence Drugs Market Overview
15.7.1 Urinary Incontinence Drugs Market by Disease Type
15.7.2 Urinary Incontinence Drugs Market by Treatment Type
16 Japan Urinary Incontinence Drugs Market
16.1 Urinary Incontinence Drugs Market Historical Value (2017-2023)
16.2 Urinary Incontinence Drugs Market Forecast Value (2024-2032)
16.2.1 Urinary Incontinence Drugs Market by Disease Type
16.2.2 Urinary Incontinence Drugs Market by Treatment Type
17 Patent Analysis
17.1 Analysis by Type of Patent
17.2 Analysis by Publication year
17.3 Analysis by Issuing Authority
17.4 Analysis by Patent Age
17.5 Analysis by CPC Analysis
17.6 Analysis by Patent Valuation
17.7 Analysis by Key Players
18 Grants Analysis
18.1 Analysis by year
18.2 Analysis by Amount Awarded
18.3 Analysis by Issuing Authority
18.4 Analysis by Grant Application
18.5 Analysis by Funding Institute
18.6 Analysis by NIH Departments
18.7 Analysis by Recipient Organization
19 Clinical Trials Analysis
19.1 Analysis by Trial Registration Year
19.2 Analysis by Trial Status
19.3 Analysis by Trial Phase
19.4 Analysis by Therapeutic Area
19.5 Analysis by Geography
20 Funding Analysis
20.1 Analysis by Funding Instances
20.2 Analysis by Type of Funding
20.3 Analysis by Funding Amount
20.4 Analysis by Leading Players
20.5 Analysis by Leading Investors
20.6 Analysis by Geography
21 Partnership and Collaborations Analysis
21.1 Analysis by Partnership Instances
21.2 Analysis by Type of Partnership
21.3 Analysis by Leading Players
21.4 Analysis by Geography
22 Supplier Landscape
22.1 Johnson & Johnson
22.1.1 Financial Analysis
22.1.2 Product Portfolio
22.1.3 Demographic Reach and Achievements
22.1.4 Mergers and Acquisition
22.1.5 Certifications
22.2 Pfizer Inc
22.2.1 Financial Analysis
22.2.2 Product Portfolio
22.2.3 Demographic Reach and Achievements
22.2.4 Mergers and Acquisition
22.2.5 Certifications
22.3 Astellas Pharma
22.3.1 Financial Analysis
22.3.2 Product Portfolio
22.3.3 Demographic Reach and Achievements
22.3.4 Mergers and Acquisition
22.3.5 Certifications
22.4 Allergan
22.4.1 Financial Analysis
22.4.2 Product Portfolio
22.4.3 Demographic Reach and Achievements
22.4.4 Mergers and Acquisition
22.4.5 Certifications
22.5 Takeda Pharmaceuticals Company
22.5.1 Financial Analysis
22.5.2 Product Portfolio
22.5.3 Demographic Reach and Achievements
22.5.4 Mergers and Acquisition
22.5.5 Certifications
22.6 Merck KGaA.
22.6.1 Financial Analysis
22.6.2 Product Portfolio
22.6.3 Demographic Reach and Achievements
22.6.4 Mergers and Acquisition
22.6.5 Certifications
22.7 Sanofi S.A.
22.7.1 Financial Analysis
22.7.2 Product Portfolio
22.7.3 Demographic Reach and Achievements
22.7.4 Mergers and Acquisition
22.7.5 Certifications
22.8 Kissei Pharmaceutical
22.8.1 Financial Analysis
22.8.2 Product Portfolio
22.8.3 Demographic Reach and Achievements
22.8.4 Mergers and Acquisition
22.8.5 Certifications
22.9 Kyorin holding
22.9.1 Financial Analysis
22.9.2 Product Portfolio
22.9.3 Demographic Reach and Achievements
22.9.4 Mergers and Acquisition
22.9.5 Certifications
22.10 Urovant Sciences
22.10.1 Financial Analysis
22.10.2 Product Portfolio
22.10.3 Demographic Reach and Achievements
22.10.4 Mergers and Acquisition
22.10.5 Certifications
22.11 Cook MyoSite
22.11.1 Financial Analysis
22.11.2 Product Portfolio
22.11.3 Demographic Reach and Achievements
22.11.4 Mergers and Acquisition
22.11.5 Certifications
22.12 elicept Therapeutics
22.12.1 Financial Analysis
22.12.2 Product Portfolio
22.12.3 Demographic Reach and Achievements
22.12.4 Mergers and Acquisition
22.12.5 Certifications
22.13 Astellas Pharma
22.13.1 Financial Analysis
22.13.2 Product Portfolio
22.13.3 Demographic Reach and Achievements
22.13.4 Mergers and Acquisition
22.13.5 Certifications
23 Urinary Incontinence Drugs Market - Distribution Model (Additional Insight)
23.1 Overview
23.2 Potential Distributors
23.3 Key Parameters for Distribution Partner Assessment
24 Key Opinion Leaders (KOL) Insights (Additional Insight)
25 Company Competitiveness Analysis (Additional Insight)
25.1 Very Small Companies
25.2 Small Companies
25.3 Mid-Sized Companies
25.4 Large Companies
25.5 Very Large Companies
26 Payment Methods (Additional Insight)
26.1 Government Funded
26.2 Private Insurance
26.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market attained a value of about USD 12028.45 million in 2023, driven by the increased geriatric patients.
The market is anticipated to grow at a CAGR of 7% during the forecast period of 2024-2032 and is likely to reach a market value of USD 22199 million by 2032.
The rising prevalence of urinary incontinence, coupled with the growing geriatric population, are among the major factors driving the market growth.
The market is driven by continuous drug approvals and research and development for their clinical trials.
The major regions of the market include the United States, EU-4 and the United Kingdom, and Japan.
There are various types of incontinence such as urge incontinence, overflow incontinence, stress incontinence, and mixed incontinence, among other type.
Drugs like anticholinergic, skeletal muscle relaxants, antidepressants, alpha-blockers, and topical estrogens, among others are used to treat this condition.
Distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies.
Key players involved in the market are Johnson & Johnson, Pfizer Inc, Astellas Pharma, Allergan, Takeda Pharmaceuticals Company, Merck KGaA., Sanofi S.A., Kissei Pharmaceutical, Kyorin Holding, Urovant Sciences, Cook MyoSite, elicept Therapeutics, and Astellas Pharma.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 3299
$2999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 6599
$5999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 8799
$7999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 9899
$8999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER